Affimed to Present at the UBS Global Healthcare Conference -- New York
17 mai 2016 05h00 HE
|
Affimed NV
HEIDELBERG, Germany, May 17, 2016 (GLOBE NEWSWIRE) -- Affimed (Nasdaq:AFMD) today announced that Dr. Adi Hoess, CEO, will present a corporate overview at the UBS Global Healthcare Conference –...
Affimed Reports Financial Results for Fourth Quarter and Year End 2015
30 mars 2016 07h30 HE
|
Affimed NV
HEIDELBERG, Germany, March 30, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer...
Affimed to Present at the Cowen and Company 36th Annual Health Care Conference
29 févr. 2016 05h07 HE
|
Affimed NV
HEIDELBERG, Germany, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer...
Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA(R) (pembrolizumab) for Patients with Hodgkin Lymphoma
25 janv. 2016 05h00 HE
|
Affimed NV
HEIDELBERG, Germany, Jan. 25, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer...
Affimed to Present at the Oppenheimer 26th Annual Healthcare Conference -- New York
01 déc. 2015 05h00 HE
|
Affimed NV
HEIDELBERG, Germany, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD) today announced that Dr. Adi Hoess, CEO, will present a corporate overview at the Oppenheimer 26th Annual Healthcare...
Affimed CEO to Present at the Jefferies 2015 Global Healthcare Conference -- London
11 nov. 2015 05h00 HE
|
Affimed NV
HEIDELBERG, Germany, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) today announced that Dr. Adi Hoess, CEO, will present a corporate overview at the Jefferies Autumn 2015 Global...
Affimed to Present Data on NK- and T-Cell Engagers at ASH
05 nov. 2015 09h28 HE
|
Affimed NV
Heidelberg, Germany, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today announced that...
Affimed Announces Significant Investment by an Existing Shareholder
14 oct. 2015 16h07 HE
|
Affimed NV
HEIDELBERG, Germany, Oct. 14, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today announced that an...
Affimed Added to Russell 2000(R) Index
30 juin 2015 05h00 HE
|
Affimed NV
HEIDELBERG, Germany, June 30, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer...
AbCheck and Pierre Fabre Pharmaceuticals Enter Into Strategic Research Partnership
17 juin 2015 05h04 HE
|
Affimed NV
HEIDELBERG, Germany, June 17, 2015 (GLOBE NEWSWIRE) -- AbCheck s.r.o, a wholly owned subsidiary of Affimed N.V., Heidelberg, Germany, and Pierre Fabre Pharmaceuticals announced today that they have...